Trial Profile
A multicentre, Open Label, Treatment Protocol of the Human Anti-TNF Monoclonal Antibody Adalimumab in Canadian Subjects With Moderate to Severe Crohn's Disease (ACCESS)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 26 Oct 2016
Price :
$35
*
At a glance
- Drugs Adalimumab (Primary)
- Indications Crohn's disease
- Focus Adverse reactions
- Acronyms ACCESS
- Sponsors Abbott Laboratories
- 27 Sep 2016 Results of pooled analysis from this and other nine trials (CLASSIC I and II, GAIN, CHARM, EXTEND, CARE, ACCESS, ADHERE) assessing the risk of serious and opportunistic infections in patients with treated with adalimumab (n=2266) published in the American Journal of Gastroenterology.
- 05 Nov 2009 New trial record